Conference Track

Updates in HCV Treatment

Source: CCO Official Conference Coverage of the 2009 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

SILEN-C1: High Rate of Virologic Response at Weeks 4 and 12 With Addition of BI 201335 to Standard of Care for First-line Treatment of Genotype 1 HCV Infection
NEXT-1: Adding Narlaprevir to Standard Peginterferon alfa-2b/Ribavirin Regimen Produces Rapid Virologic Response in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Infection
SPRINT-1: Up to 55% of Genotype 1 HCV Patients With Null Response After 4 Weeks of Peginterferon/Ribavirin Lead-in Achieved SVR With Triple-Therapy Regimen Containing Boceprevir
PROVE 3: SVR Improved With Telaprevir Combined With Peginterferon alfa-2a/Ribavirin Therapy in Genotype 1 HCV Patients Failing Previous Regimen; 1-Year Durability Demonstrated
INFORM-1: First Interferon-Free Combination Therapy With Direct-Acting Antiviral Agents RG7128 and RG7227 Safe and Effective in Chronic Genotype 1 HCV Patients
Final Results of Study C208: High Rates of SVR Achieved With Telaprevir/Peginterferon/Ribavirin Combination Therapy in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection
PARADIGM: High-Dose Ribavirin Plus Peginterferon alfa-2a not Associated With Improved SVR Rate in HCV/HIV-Coinfected Patients
Addition of Thymosin alpha-1 to Peginterferon alfa-2a Plus Ribavirin in Previous Nonresponder, Primarily Genotype 1 HCV Population Does Not Increase SVR Rate by Intent-to-Treat Analysis
Among HCV-Infected Patients With Poor Prognostic Indicators, Telaprevir-Based Therapy Significantly Improved Virologic Response vs Standard of Care
Robust Antiviral Activity of NS5B Polymerase Inhibitor MK-3281 in Patients Infected With Genotype 1b HCV During 7-Day Monotherapy
Preliminary Data Suggest Virologic Benefit of Nitazoxanide Plus Peginterferon alfa-2a/Ribavirin in Cirrhotic Patients Infected With Genotype 1 HCV Who Failed Previous Peginterferon/Ribavirin Therapy
Early Response to Boceprevir/Peginterferon/Ribavirin Predicts Outcomes in the SPRINT-1 Study

Expert Analysis

Updates in HCV Treatment

Faculty:

Michael P. Manns, MD
David R. Nelson, MD
Tram T. Tran, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite new phase II data on the safety and efficacy of protease inhibitors used in combination with standard peginterferon/ribavirin therapy for treatment-naive and treatment-experienced patients with genotype 1 HCV infection
Summarize recent findings on predictors of response to peginterferon/ribavirin therapy among patients infected with genotype 1 HCV
Articulate the latest clinical trial results on the safety, efficacy, and resistance profile of combination HCV therapy with HCV protease and polymerase inhibitors
Describe emerging new data on the safety and efficacy of novel HCV polymerase inhibitors

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: December 30, 2009

Expiration Date: December 29, 2010

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.